1.Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China.
Yan GAO ; Guang NING ; Wei-Ping JIA ; Zhi-Guang ZHOU ; Zhang-Rong XU ; Zhi-Min LIU ; Chao LIU ; Jian-Hua MA ; Qiang LI ; Lu-Lu CHENG ; Chong-Yuan WEN ; Shu-Yu ZHANG ; Qi ZHANG ; Durisala DESAIAH ; Vladimir SKLJAREVSKI
Chinese Medical Journal 2010;123(22):3184-3192
BACKGROUNDDuloxetine, a selective serotonin and noradrenaline reuptake inhibitor, has been shown to be effective in treatment of diabetic peripheral neuropathic pain and approved for the management of patients with diabetic peripheral neuropathic pain (DPNP) in the United States, European Union, and many other countries. This study assessed the efficacy and safety of duloxetine in Chinese patients with diabetic peripheral neuropathic pain.
METHODSThis double-blind, randomized, placebo-controlled, flexible-dose study treated adult patients with diabetic peripheral neuropathic pain and baseline Brief Pain Inventory (BPI) 24-hour average pain severity ratings ≥ 4 with duloxetine 60 mg to 120 mg once daily or placebo for 12 weeks. Dose adjustments of duloxetine or matching placebo were based upon investigator's judgment of clinical response. Change from baseline to endpoint in BPI average pain was the primary efficacy outcome. Secondary outcome measures included BPI-severity and -Interference, Patient Global Impression of Improvement, Clinical Global Impressions of Severity, EuroQol: 5 Dimensions, Athens Insomnia Scale, and safety measures.
RESULTSOf 215 patients randomized, 88.4% and 82.1% of patients in placebo and duloxetine groups, respectively, completed the study. Mean change from baseline to endpoint in BPI average pain was not statistically different between the treatment groups (P = 0.124). Duloxetine- treated patients showed significantly greater pain reduction compared with those in placebo group at weeks 1, 2, and 4 (P = 0.004, P = 0.009, and P = 0.006, respectively), but not at weeks 8 (P = 0.125) and 12 (P = 0.107). Duloxetine-treated patients experienced statistically significant improvement in Patient Global Impression of Improvement, Clinical Global Impression of Severity, area under the curve for pain relief, BPI-severity pain right now, and BPI-interference walking ability. Patients treated with duloxetine 120 mg once daily showed significantly greater pain reduction on the Brief Pain Inventory average pain score relative to placebo. Duloxetine-treated patients reported nausea, somnolence, anorexia, and dysuria significantly more than placebo.
CONCLUSIONSAlthough the primary study endpoint was not achieved, the overall observed response pattern suggests the efficacy of duloxetine in the treatment of Chinese patients with diabetic peripheral neuropathic pain. The safety profile for duloxetine is similar to that reported in other global trials.
Adrenergic Uptake Inhibitors ; therapeutic use ; Aged ; Diabetic Neuropathies ; drug therapy ; Double-Blind Method ; Duloxetine Hydrochloride ; Female ; Humans ; Male ; Middle Aged ; Placebos ; Thiophenes ; therapeutic use ; Treatment Outcome
2.Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
Wen-Yuan WU ; Gang WANG ; Susan G BALL ; Durisala DESAIAH ; Qiu-Qing ANG
Chinese Medical Journal 2011;124(20):3260-3268
BACKGROUNDDuloxetine is approved for the treatment of generalized anxiety disorder (GAD) in the United States and elsewhere. This study aimed to assess the efficacy, tolerability, and safety of duloxetine in Chinese patients with GAD.
METHODSThis 9-site study consisted of double-blind treatment for 15 weeks either with duloxetine 60 - 120 mg or with placebo. Patients with at least moderately severe GAD and a Sheehan Disability Scale (SDS) global functioning impairment total score ≥ 12 were included in this study. Patients who were randomly assigned to duloxetine received 60 mg for 7 weeks; at that point, for nonresponders the dose was increased to 120 mg for the remaining 8 weeks. The primary efficacy measure was mean change from baseline to endpoint on the Hospital Anxiety and Depression Scale-Anxiety subscale score (HADS-A). Secondary efficacy measures included the Hamilton Anxiety Rating Scale (HAMA), the SDS, and pain measures. Safety and tolerability were assessed.
RESULTSBaseline characteristics did not differ significantly between treatment groups. Mean age of the subjects (n = 210) was 37.6 years, 50.5% were female, and 74.3% completed the 15 weeks treatment. Patients treated with duloxetine had significantly greater improvement compared to placebo on the HADS-A (mean change -6.6 vs. -4.9, respectively, P = 0.022). Improvement in anxiety was greater with duloxetine treatment at 7 weeks and continued through 15 weeks for both the HADS-A and the HAMA total score (0.01 ≤ P < 0.05). Compared with placebo, duloxetine was also associated with greater improvement on most secondary measures, but not on the SDS global functioning score. Nausea, dizziness, and somnolence occurred significantly more frequently as treatment-emergent adverse events with duloxetine treatment compared with placebo treatment.
CONCLUSIONSDuloxetine 60 - 120 mg once daily is effective and well-tolerated for the treatment of patients with GAD in China.
Adult ; Antidepressive Agents ; adverse effects ; therapeutic use ; Anxiety Disorders ; drug therapy ; Double-Blind Method ; Duloxetine Hydrochloride ; Female ; Humans ; Male ; Middle Aged ; Thiophenes ; adverse effects ; therapeutic use ; Treatment Outcome
3.Clinical characteristic and fecal microbiota responses to probiotic or antidepressant in patients with diarrhea-predominant irritable bowel syndrome with depression comorbidity: a pilot study.
Lu ZHANG ; Yi-Xuan LIU ; Zhe WANG ; Xiao-Qi WANG ; Jing-Jing ZHANG ; Rong-Huan JIANG ; Xiang-Qun WANG ; Shi-Wei ZHU ; Kun WANG ; Zuo-Jing LIU ; Huai-Qiu ZHU ; Li-Ping DUAN
Chinese Medical Journal 2019;132(3):346-351
Adolescent
;
Adult
;
Aged
;
Antidepressive Agents
;
therapeutic use
;
Body Mass Index
;
Depression
;
microbiology
;
Diarrhea
;
microbiology
;
Duloxetine Hydrochloride
;
therapeutic use
;
Feces
;
microbiology
;
Humans
;
Irritable Bowel Syndrome
;
drug therapy
;
microbiology
;
Middle Aged
;
Pilot Projects
;
Probiotics
;
therapeutic use
;
RNA, Ribosomal, 16S
;
genetics
;
Young Adult
4.Treatment of Persistent Somatoform Pain Disorder by Floating Needle Therapy and Duloxetine.
Wan-wen REN ; Zhi-ying ZHOU ; Mi-mi XU ; Sen LONG ; Guang-zheng TANG ; Hong-jing MAO ; Shu-lin CHEN
Chinese Journal of Integrated Traditional and Western Medicine 2016;36(2):166-171
OBJECTIVETo evaluate clinical effect and safety of floating needle therapy and duloxetine in treating patients with persistent somatoform pain disorder (PSPD).
METHODSTotally 108 PSPD patients were randomly assigned to the floating needle treatment group, the duloxetine treatment group, and the placebo treatment group, 36 in each group. Patients in the floating needle treatment group received floating needle therapy and placebo. Those in the duloxetine treatment group received duloxetine and simulated floating needle therapy. Those in the placebo treatment group received the placebo and simulated floating needle therapy. All treatment lasted for six weeks. Efficacy and adverse reactions were evaluated using Simple McGill pain scale (SF-MPQ) and Treatment Emergent Symptom Scale (TESS) before treatment and immediately after treatment, as well as at the end of 1st, 2nd, 4th, and 6th week of treatment, respectively. Hamilton Depression Scale (HAMD, 17 items), Hamilton Anxiety Scale (HAMA) were assessed before treatment and at the end of 1st, 2nd, 4th, and 6th week of treatment, respectively. Patients in the floating needle treatment group and the duloxetine treatment group with the total reducing score rate of SF-MPQ in Pain Rating index (PRI) ≥ 50% after 6 weeks' treatment were involved in the follow-up study.
RESULTS(1) Compared with the same group before treatment, SF-MPQ score, HAMD score and HAMA total scores all decreased in all the three groups at the end of 1st, 2nd, 4th, and 6th week of treatment (P < 0.05, P < 0.01). Besides , each item of SF-MPQ significantly decreased immediately after treatment in the floating needle treatment group (P < 0.01). Compared with the placebo treatment group, SF-MPQ, HAMD, and HAMA total score in the floating needle treatment group significantly decreased after 1, 2, 4, and 6 weeks of treatment (P < 0.05, P < 0.01). SF-MPQ score, HAMD score and HAMA total score in the duloxetine treatment group also significantly decreased after 2, 4, and 6 weeks of treatment (P < 0.05, P < 0.01). (2) There were 3 patients (8.3%) who had adverse reactions in the floating needle treatment group, 17 (50.0%) in the duloxetine treatment group, and 7 (21.2%) in the placebo treatment group. Compared with the placebo treatment group, the incidence of adverse reaction increased in the duloxetine treatment group (χ² = 6.04, P < 0.05). Besides, it was higher in the duloxetine treatment group than in the floating needle treatment group (χ² = 14.9, P < 0.05). (3) There were 19 patients in the floating needle treatment group and 17 patients in the duloxetine treatment group involved in the follow-up study. Compared with 6 weeks after treatment, no significant difference was observed at 3 and 6 months after treatment in the score of SF-MPQ, HAMD, and HAMA in the floating needle treatment group and the duloxetine treatment group. No significant difference was observed between the two groups (P > 0.05). There were 5 patients (29.4%) who had adverse reactions in the duloxetine treatment group, and no adverse reactions were observed in the floating needle treatment group. The adverse reaction rate was significantly different between the two groups (χ² = 4.26, P < 0.05).
CONCLUSIONSFloating needle therapy and duloxetine were effective in treatment of patients with PSPD. However, floating needle therapy could relieve pain more rapidly than duloxetine, with obviously less adverse reactions.
Acupuncture Therapy ; methods ; Analgesics ; therapeutic use ; Anxiety Disorders ; Duloxetine Hydrochloride ; therapeutic use ; Follow-Up Studies ; Humans ; Needles ; Pain ; Pain Management ; methods ; Pain Measurement ; Psychiatric Status Rating Scales ; Somatoform Disorders ; therapy ; Treatment Outcome
5.A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient.
Ji Hyun SONG ; Si Yeon KIM ; Jae Kyoung SHIN ; So Dam HONG ; Kyu Sung RIM ; Ha Na PARK ; Joo Ho LEE ; Yun Bin LEE ; Seung Hun OH ; Seong Gyu HWANG
The Korean Journal of Gastroenterology 2016;67(4):216-219
Entecavir (Baraclude®) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying. Most common adverse reactions caused by entecavir are headache, fatigue, dizziness, and nausea. Until now, there has been no report of peripheral neuropathy as a side effect associated with entecavir treatment. Herein, we report a case of peripheral neuropathy which probably occurred after treatment with entecavir in a hepatitis B patient. The possibility of the occurrence of this side effect should be carefully taken into consideration when a patient takes a high dose of entecavir for a long period of time or has risk factors for neuropathy at the time of initiating entecavir therapy.
Administration, Oral
;
Antiviral Agents/*adverse effects/therapeutic use
;
Brain/diagnostic imaging
;
Drug Therapy, Combination
;
Duloxetine Hydrochloride/therapeutic use
;
Glucocorticoids/therapeutic use
;
Guanine/adverse effects/*analogs & derivatives/therapeutic use
;
Hepatitis B, Chronic/drug therapy
;
Humans
;
Male
;
Middle Aged
;
Polyneuropathies/*diagnosis/drug therapy/etiology
;
Prednisolone/therapeutic use
;
Pregabalin/therapeutic use
;
Tomography, X-Ray Computed